Lancet. 2022 Mar 26;399(10331):1266-1278. doi: 10.1016/S0140-6736(21)02347-3.
Most countries have made little progress in achieving the Sustainable Development Goal (SDG) target 3.4, which calls for a reduction in premature mortality from non-communicable diseases (NCDs) by a third from 2015 to 2030. In this Health Policy paper, we synthesise the evidence related to interventions that can reduce premature mortality from the major NCDs over the next decade and that are feasible to implement in countries at all levels of income. Our recommendations are intended as generic guidance to help 123 low-income and middle-income countries meet SDG target 3.4; country-level applications require additional analyses and consideration of the local implementation and utilisation context. Protecting current investments and scaling up these interventions is especially crucial in the context of COVID-19-related health system disruptions. We show how cost-effectiveness data and other information can be used to define locally tailored packages of interventions to accelerate rates of decline in NCD mortality. Under realistic implementation constraints, most countries could achieve (or almost achieve) the NCD target using a combination of these interventions; the greatest gains would be for cardiovascular disease mortality. Implementing the most efficient package of interventions in each world region would require, on average, an additional US$18 billion annually over 2023-30; this investment could avert 39 million deaths and generate an average net economic benefit of $2·7 trillion, or $390 per capita. Although specific clinical intervention pathways would vary across countries and regions, policies to reduce behavioural risks, such as tobacco smoking, harmful use of alcohol, and excess sodium intake, would be relevant in nearly every country, accounting for nearly two-thirds of the health gains of any locally tailored NCD package. By 2030, ministries of health would need to contribute about 20% of their budgets to high-priority NCD interventions. Our report concludes with a discussion of financing and health system implementation considerations and reflections on the NCD agenda beyond the SDG target 3.4 and beyond the SDG period.
大多数国家在实现可持续发展目标 3.4 方面进展甚微,该目标呼吁到 2030 年将非传染性疾病导致的过早死亡率降低三分之一。在这份卫生政策文件中,我们综合了与未来十年内可减少主要非传染性疾病过早死亡率且在各收入水平国家均可行的干预措施相关的证据。我们的建议旨在提供一般性指导,以帮助 123 个低收入和中等收入国家实现可持续发展目标 3.4;国家层面的应用需要对当地实施和利用情况进行额外的分析和考虑。在与 COVID-19 相关的卫生系统中断的背景下,保护当前的投资并扩大这些干预措施尤为重要。我们展示了如何使用成本效益数据和其他信息来确定适合当地情况的干预措施一揽子计划,以加速非传染性疾病死亡率的下降。在现实的实施限制下,大多数国家可以通过这些干预措施的组合来实现(或几乎实现)非传染性疾病目标;心血管疾病死亡率的降幅将最大。在每个世界区域实施最有效的干预措施一揽子计划,平均每年需要额外投资 180 亿美元(2023 年至 2030 年);这项投资可以避免 3900 万人死亡,并产生平均 2.7 万亿美元的净经济效益,或人均 390 美元。虽然具体的临床干预途径会因国家和地区而异,但减少行为风险的政策,如吸烟、有害饮酒和过量摄入钠,在几乎每个国家都相关,占任何适合当地情况的非传染性疾病一揽子计划的健康收益的近三分之二。到 2030 年,各国卫生部需要将其预算的约 20%用于非传染性疾病高优先干预措施。我们的报告最后讨论了融资和卫生系统实施方面的考虑因素,以及对可持续发展目标 3.4 之外和可持续发展目标周期之外的非传染性疾病议程的思考。